ARS Pharmaceuticals annual net debt
2020
2021
2022
2023
2024
2025
ARS Pharmaceuticals Net Debt Growth & History (SPRY)
ARS Pharmaceuticals's net debt was $55.1M for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $55.1M | $105.8M | — |
| 2024 | 2024-12-31 | −$50.8M | $19.9M | — |
| 2023 | 2023-12-31 | −$70.7M | $139.3M | — |
| 2022 | 2022-12-31 | −$210.0M | −$155.8M | — |
| 2021 | 2021-12-31 | −$54.2M | $329.1M | — |
| 2020 | 2020-12-31 | −$383.3M | — | — |
ARS Pharmaceuticals quarterly net debt
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $88.5M | $138.4M | — |
| Q1 2026 | 2026-03-31 | $72.2M | $112.0M | — |
| Q4 2025 | 2025-12-31 | $55.1M | $105.8M | — |
| Q3 2025 | 2025-09-30 | $38.2M | $77.8M | — |
| Q2 2025 | 2025-06-30 | −$49.9M | −$13.4M | — |
| Q1 2025 | 2025-03-31 | −$39.8M | $16.0M | — |
| Q4 2024 | 2024-12-31 | −$50.8M | $19.9M | — |
| Q3 2024 | 2024-09-30 | −$39.6M | $20.6M | — |
| Q2 2024 | 2024-06-30 | −$36.5M | $82.2M | — |
| Q1 2024 | 2024-03-31 | −$55.8M | $31.6M | — |
| Q4 2023 | 2023-12-31 | −$70.7M | $139.3M | — |
| Q3 2023 | 2023-09-30 | −$60.2M | $142.8M | — |
| Q2 2023 | 2023-06-30 | −$118.6M | $95.1M | — |
| Q1 2023 | 2023-03-31 | −$87.4M | $141.0M | — |
| Q4 2022 | 2022-12-31 | −$210.0M | −$155.8M | — |
| Q3 2022 | 2022-09-30 | −$203.0M | $91.5M | — |
| Q2 2022 | 2022-06-30 | −$213.7M | $143.2M | — |
| Q1 2022 | 2022-03-31 | −$228.4M | $142.8M | — |
| Q4 2021 | 2021-12-31 | −$54.2M | $329.1M | — |
| Q3 2021 | 2021-09-30 | −$294.5M | — | — |
| Q2 2021 | 2021-06-30 | −$357.0M | — | — |
| Q1 2021 | 2021-03-31 | −$371.2M | — | — |
| Q4 2020 | 2020-12-31 | −$383.3M | — | — |
ARS Pharmaceuticals net debt trends
Over the last five fiscal years, ARS Pharmaceuticals's net debt increased from −$383.3M to $55.1M, a change of $438.4M. The latest reported quarter, Q2 2026, shows $88.5M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗